Impact of Preventive Treatment With Long-Acting β2-Adrenergic Agonists and Inhaled Corticosteroids on the Morbidity and Mortality of Severe Asthma Exacerbations in 1543 Patients;Impacto del tratamiento preventivo con agonistas adrenérgicos β2 de acción larga y glucocorticoides inhalados en la morbimortalidad de 1.543 episodios de exacerbación grave de asma

Archivos de Bronconeumologia

Volumn 45, Issue 11, 2009, Pages 545-549

  Plaza, Vicente ^a   Bellido Casado, Jesús ^a   Rodrigo, Gustavo J ^b   Solarte, Javier ^c   Rodríguez Trigo, Gema ^d,e   Sepúlveda, Ricardo ^f   Neffen, Hugo ^g   Perpiñá, Miguel ^h  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f INSTITUTO NACIONAL DEL TÓRAX   (Chile)

^g 'O Alassia' Children's Hospital   (Argentina)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Asthma; Inhaled corticosteroids; Morbidity; Mortality; Preventive treatment of asthma; Severe asthma exacerbation

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LONG ACTING DRUG; SALMETEROL;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MODERATE PERSISTENT ASTHMA; MORBIDITY; MORTALITY; PH; RETROSPECTIVE STUDY; SEVERE PERSISTENT ASTHMA;

EID: 70350028207     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2009.05.009     Document Type: Article

References (27)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. 2006. Disponible en: http://www.ginasthma.com.
2. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2007. Disponible en: http://www.sign.ac.uk/guidelines.
3. Nacional Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute; 2007.
4. Guía Española para el Manejo del Asma (GEMA). Disponible en: http://www.gemasma.com.
5. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
6. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
7. Sears M.R., Ottosson A., Radner F., and Suissa S. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33 (2009) 21-32
8. Rodrigo G.J., Plaza Moral V., García-Marcos L., and Castro-Rodríguez J.A. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review with meta-analysis. Pulm Pharmacol Ther 22 (2009) 9-19
9. Speizer F.E., Doll R., Heaf P., and Strang L.B. Investigation into use of drugs preceding death from asthma. Br Med J 10 (1968) 339-343
10. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 29 (1989) 917-922
11. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 45 (1990) 170-175
12. Beasley R., Martínez F.D., Hackshaw A., Rabe K.F., Sterk P.J., and Djukanovic R. Safety of long-acting β-agonists: urgent need to clear the air remains. Eur Respir J 33 (2009) 3-5
13. Rodrigo G.J., Plaza V., Bardagí S., Perpiñá M., and Salas J. Factors associated with mortality in patients hospitalized for severe acute asthma over a ten year period (1994-2004) in Spain and Latin-america. J Bras Pneumol 34 (2008) 546-551
14. Ernst P., McIvor A., Ducharme F.M., Boulet L.P., FitzGerald M., Chapman K.R., et al. Canadian Asthma Guideline Group. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 145 (2006) 692-694
15. Domingo Ribas C. Mortalidad por betaagonistas o el riesgo de la inferencia. Arch Bronconeumol 43 (2007) 355-357
16. Bellido Casado J., Plaza V., Bardagí S., Cosano J., López Viña A., Martínez Moragón E., et al. ¿Disminuye la incidencia de asma de riesgo vital en España?. Arch Bronconeumol 42 (2006) 522-525
17. López-Campos J.L., Cayuela A., Rodríguez-Domínguez S., and Vigil E. Temporal trends in asthma mortality over 30 years. J Asthma 45 (2008) 611-614
18. Rodríguez-Trigo G., Plaza V., Picado C., and Sanchis J. El tratamiento según la guía de la Global Initiative for Asthma (GINA) reduce la morbimortalidad de los pacientes con asma de riesgo vital. Arch Bronconeumol 44 (2008) 192-196
19. Haahtela T., Klaukka T., Koskela K., Erhola M., and Laitinen L.A. Working Group of the Asthma Programme in Finland 1994-2004. Asthma programme in Finland: a community problem needs community solutions. Thorax 56 (2001) 806-814
20. Sánchez-Bahíllo M., García-Marcos L., Pérez-Fernández V., Martínez-Torres A.E., and Sánchez-Solís M. Evolución de la mortalidad por asma en España, 1960-2005. Arch Bronconeumol 45 (2009) 123-128
21. 2-adrenérgicos de acción prolongada en el asma bronquial. Med Clin (Barc) 128 (2007) 352-354
22. Van der Woude H.J., Winter T.H., and Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting b2 agonists. Thorax 56 (2001) 529-535
23. Lee D.K.C., Jackson C.M., Bates C.E., and Lipworth B.J. ß2 adrenoceptor genotype-16 in asthmatic cross tolerance to salbutamol occurs independently patients receiving regular formoterol or salmeterol. Thorax 59 (2004) 662-667
24. Nelson H.S. Is there a problem with inhaled long-acting b-adrenergic agonists?. J Allergy Clin Immunol 117 (2006) 3-16
25. Matz J., Emmett A., Rickard K., and Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 107 (2001) 783-789
26. Morell F., Genover T., Muñoz X., García-Aymerich J., Ferrer J., and Cruz M.J. Rate and characteristics of asthma exacerbations: the ASMAB I Study. Arch Bronconeumol 44 (2008) 303-311
27. Carroll C.L., Bhandari A., Schramm C.M., and Zucker A.R. Chronic inhaled corticosteroids do not affect the course of acute severe asthma exacerbations in children. Pediatr Pulmonol 41 (2006) 1213-1217